Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
18 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Exagen Inc.’s names, not what it holds today.
Patents granted
18
18 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 1 in 2024 and 1 in 2023
Applications published
34
since 2001, to Dec 31, 2025
Names they are printed under
4
a former name, its own name
By yearGrantedApplications published
'05'06'09'10'11'12'13'15'18'19'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Analysis of biological materials6
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Exagen Diagnostics, Inc. a former name
US, as the owner printed on each patent
25 publishedExagen Inc. its own name
US, as the owner printed on each patent
1 publishedExagen Inc. its own name
named as the applicant on its applications, in US
7 publishedExagen Diagnostics, Inc. a former name
named as the applicant on its applications, in US
1 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Oct 21, 2025 | 12,449,427 | Methods for treating and diagnosing systemic lupus erythematosus | Analysis of biological materials | Exagen Inc. |
| Jul 29, 2025 | 12,372,535 | Methods for diagnosing systemic lupus erythematosus | Analysis of biological materials | Exagen Inc. |
| Jan 30, 2024 | 11,885,812 | Methods for diagnosing systemic lupus erythematosus | Analysis of biological materials | Exagen Inc. |
| Sep 19, 2023 | 11,761,965 | Methods for diagnosing systemic lupus erythematosus | Analysis of biological materials | Exagen Inc. |
| Dec 20, 2022 | 11,531,033 | Methods for treating and diagnosing systemic lupus erythematosus | Analysis of biological materials | Exagen Inc. |
| Jun 14, 2022 | 11,360,099 | Methods for diagnosing systemic lupus erythematosus | Analysis of biological materials | Exagen Inc. |
| Nov 20, 2018 | 10,132,813 | Methods for diagnosing systemic lupus erythematosus | Analysis of biological materials | Exagen Diagnostics, Inc. |
| Jul 24, 2012 | 8,227,589 | Biomarkers for inflammatory bowel disease and irritable bowel syndrome | Biotechnology | Exagen Diagnostics, Inc. |
| Jul 17, 2012 | 8,222,390 | Biomarkers for inflammatory bowel disease and irritable bowel syndrome | Biotechnology | Exagen Diagnostics, Inc. |
| Dec 6, 2011 | 8,073,630 | Pharacogenetic method for prediction of the efficacy of methotrexate monotherapy in recent-onset arthritis | Computer technology | Exagen Diagnostics, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Aug 29, 2024 | 2024/0288441 | METHODS FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS | Analysis of biological materials | Exagen Inc. · patent 12,372,535 granted from it |
| Jan 4, 2024 | 2024/0003902 | METHODS FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS | Analysis of biological materials | Exagen Inc. · patent 11,885,812 granted from it |
| Jul 20, 2023 | 2023/0228768 | METHODS FOR TREATING AND DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS | Analysis of biological materials | Exagen Inc. |
| Jun 22, 2023 | 2023/0194553 | METHODS FOR TREATING AND DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS | Analysis of biological materials | Exagen Inc. · patent 12,449,427 granted from it |
| Jun 22, 2023 | 2023/0194548 | METHODS FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS | Analysis of biological materials | Exagen Inc. · patent 11,761,965 granted from it |
| Sep 22, 2022 | 2022/0299510 | METHODS FOR DIAGNOSING, PROGNOSING AND MONITORING TREATMENT FOR THROMBOSIS IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Pharmaceuticals | Exagen Inc. |
| Sep 1, 2022 | 2022/0276259 | METHODS FOR DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS | Analysis of biological materials | Exagen Inc. |
| Jul 22, 2021 | 2021/0220389 | METHODS FOR DIAGNOSING, PROGNOSING AND MONITORING TREATMENT FOR THROMBOSIS IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Pharmaceuticals | Exagen Inc. |
| Jan 24, 2019 | 2019/0025326 | Methods for Diagnosing Systemic Lupus Erythematosus | Analysis of biological materials | Exagen Diagnostics, Inc. · patent 11,360,099 granted from it |
| Dec 24, 2015 | 2015/0369824 | Methods for treating and diagnosing Systemic Lupus Erythematosus | Analysis of biological materials | Exagen Diagnostics, Inc. · patent 11,531,033 granted from it |
What it applied for, 2024 to 2025: Analysis of biological materials 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.